ERBB2 and breast carcinoma: However, when we queried bc-GenExMiner, even though we found that IL12A is more expressed in HER2-positive tumors (n = 778) than in HER2-negative ones (n = 4581) (Fig. 6D), IL12A expression level is not a significant predictive marker for DFS or DMFS in HER-positive breast cancer patients (Fig. 6E, high versus low IL12A p = 0.1124 and p = 7269).